Genetic Test Reimbursement Issues Get Top Billing On SACGHS Priority List
This article was originally published in The Gray Sheet
Executive Summary
Concerns that inadequate genetic test reimbursement could hinder lab adoption of the technology have spurred the HHS Secretary's Advisory Committee on Genetics, Health & Society to rank the issue first on its list of priorities for in-depth analysis
You may also be interested in...
SACGHS Plans To Develop Genetic Test Reimbursement Recommendations
A commitment by CMS to redefine predisposition and predictive genetic tests as diagnostic lab tests could improve coverage of the technology, according to a 1SACGHS draft document
SACGHS Plans To Develop Genetic Test Reimbursement Recommendations
A commitment by CMS to redefine predisposition and predictive genetic tests as diagnostic lab tests could improve coverage of the technology, according to a 1SACGHS draft document
McClellan Urges Rigor In Pharmacogenomic R&D: Less Art, More Science
Linking microarray results to clinical outcomes will provide a more stable scientific platform for product development, FDA Commissioner Mark McClellan emphasized during an inaugural speech at the National Cancer Institute Director's Seminar Series